Viking Therapeutics Reports Wider Q3 Loss As VK2735 Phase 3 Programs Advance
Viking Therapeutics (VKTX) reported a wider Q3 2026 net loss of $1.55 per share, up from $0.81 in Q3 2025, due to higher R&D and administrative expenses. The company held $960M in cash and equivalents. Its lead program, VK2735, is in Phase 3 trials for obesity, with results expected in 2027. Additional programs include VK3019, VK2809, and VK0214. The stock traded between $23.82 and $43.15 over the past year.
How this was made
The 30-second read
Why it matters
The wider loss highlights higher R&D spend as the company advances multiple Phase 3 trials, potentially affecting valuation.
Market read
Earnings miss may trigger short‑term downside, but strong cash position and advancing trials could support longer‑term investors.
What to watch
Positive Phase 3 progress on VK2735 may offset short‑term loss concerns.
Background
Viking Therapeutics is a clinical‑stage biotech developing obesity and metabolic disease programs.
Ticker impact
Q3 2026 results show a wider net loss of $183.2M versus $90.8M a year earlier, plus cash balance of $960M.
likely pressure as investors price in the larger loss
Earnings miss with higher expenses typically triggers short-term sell pressure.
Market effects
May dampen sentiment in the obesity‑focused biotech sub‑sector.
Limited to US‑listed biotech investors.
Low; impact confined to VKTX and peers.
Counterpoint
The cash runway of $960M could support upcoming Phase 3 trials, offering a longer‑term upside.
Key entities
- companyViking Therapeutics, Inc.
Clinical‑stage biopharma focused on obesity and metabolic diseases.
